试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-11
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
编号:NCT03005184登记状态:入组前撤回企业 / 申办者:Vanderbilt University Medical Center
药物 / 成分:Valsartan 80 mg bid、Enalapril 10 mg bid、Sacubitril-Valsartan 200 mg bid、Icatibant
登记的停止原因(原文):Study is being redesigned and submitted as a new study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-10
Refeeding Syndrome in Cancer Patients
编号:NCT02534181登记状态:入组前撤回企业 / 申办者:University of Sao Paulo
药物 / 成分:Caloric Management Protocol
登记的停止原因(原文):Logistical issues
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-10
Randomized Phase II Trial of Chemoembolization and Sorafenib
编号:NCT02908165登记状态:入组前撤回企业 / 申办者:Yale University
药物 / 成分:conventional TACE in combination with sorafenib, administered on a continuous schedule、conventional TACE in combination with sorafenib, administered on a sequential schedule
登记的停止原因(原文):A future study will be taking place using the same patient population.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-10
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s
编号:NCT03079973登记状态:入组前撤回企业 / 申办者:Polichem S.A.
药物 / 成分:P-3073 (calcipotriene 0.005%)、Vehicle of P-3073
登记的停止原因(原文):Project development priorities changed.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-10
Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis
编号:NCT03094468登记状态:入组前撤回企业 / 申办者:Polichem S.A.
药物 / 成分:P-3058 (terbinafine hydrochloride 10%)、Vehicle of P-3058
登记的停止原因(原文):Project development priorities changed
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-09
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department
编号:NCT01660867登记状态:入组前撤回企业 / 申办者:Seoul National University Hospital
药物 / 成分:3% saline + oral placebo、0.9% saline + oral dexamethasone
登记的停止原因(原文):there was no eligible patients
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-09
A Study of Epidural Bupivacain-soaked Absorbable Gelatin Sponge on Post-operative Pain in Lumbar Laminectomy
编号:NCT01847339登记状态:入组前撤回企业 / 申办者:The Cleveland Clinic
药物 / 成分:bupivacaine、saline solution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-09
Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema
编号:NCT01849159登记状态:入组前撤回企业 / 申办者:Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
药物 / 成分:Mesenchymal stem cells、Reference therapy: 400 mL of 0.9% NaCl solution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-09
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
编号:NCT02348255登记状态:入组前撤回企业 / 申办者:University of California, Davis
药物 / 成分:Electric Field Therapy、Bevacizumab、Carmustine、Quality-of-Life Assessment
登记的停止原因(原文):Poor Accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-09
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
编号:NCT03343678登记状态:入组前撤回企业 / 申办者:Boehringer Ingelheim
药物 / 成分:Venetoclax、BI 836826
登记的停止原因(原文):Company strategic decision
查看官方原始记录 ↗